Women with hormone receptor-positive, HER2-negative metastatic breast cancer benefit from switching from an aromatase inhibitor to fulvestrant in palbociclib combination therapy when an ESR1 mutation is detected without disease progression, phase 3 PADA-1 trial data show.
